Triptorelin doesn't prevent chemo-induced ovarian failure

May 27, 2016

(HealthDay)—Triptorelin plus norethisterone (GnRHa) does not prevent chemotherapy-induced premature ovarian failure (POF) in young patients with lymphoma, according to a study published online May 23 in the Journal of Clinical Oncology.

Isabelle Demeestere, M.D., Ph.D., from the Université Libre de Bruxelles in Belgium, and colleagues reported the final analysis of a cohort of 129 patients with lymphoma who were randomized to receive GnRHa or norethisterone alone (control) during chemotherapy. After two, three, four, and five to seven years of follow-up, ovarian function and fertility were reported. Overall, 67 patients (26.21 ± 0.64 years of age) had available data after a median follow-up of 5.33 and 5.58 years in the GnRHa and control groups, respectively.

The researchers found that the risk of POF was significantly increased according to age (P = 0.047), the conditioning regimen for transplant (P = 0.002), and the cumulative dose of cyclophosphamide >5 g/m² (P = 0.019); the risk was not increased with co-administration of GnRHa during chemotherapy (odds ratio, 0.702; P = 0.651). Both groups had similar ovarian reserve, evaluated using anti-Müllerian hormone and follicle-stimulating hormone levels. In the GnRHa and control groups, 53 and 43 percent, respectively, achieved pregnancy (P = 0.467).

"These results reopen the debate about the drug's benefit in that it should not be recommended as standard for fertility preservation in patients with ," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; triptorelin was provided by the Ipsen Pharmaceutical Group.

Explore further: Triptorelin doesn't avert early ovarian failure in lymphoma

More information: Abstract
Full Text
Editorial

Related Stories

Triptorelin doesn't avert early ovarian failure in lymphoma

November 7, 2012
(HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure (POF), according ...

Long-term outcomes of preventing premature menopause during chemotherapy

December 22, 2015
Compared with receiving chemotherapy alone, women with breast cancer who also received the hormonal drug triptorelin to achieve ovarian suppression had a higher long-term probability of ovarian function recovery, without ...

High doses of triptorelin needed for ovarian suppression in SLE

May 4, 2015
(HealthDay)—For female patients with childhood-onset systemic lupus erythematosus (SLE) who require treatment with cyclophosphamide, sustained complete ovarian suppression is achieved in 90 percent of the patients with ...

Comparing chemical and surgical castration for prostate cancer

December 23, 2015
Surgical castration to remove the testicles (orchiectomy) of men with metastatic prostate cancer was associated with lower risks for adverse effects compared with men who underwent medical castration with gonadotropin-releasing ...

Intraperitoneal chemo offers lasting benefit in ovarian cancer

March 27, 2015
(HealthDay)—Intraperitoneal (IP) chemotherapy offers lasting benefit for patients with advanced ovarian cancer, according to a study published online March 23 in the Journal of Clinical Oncology.

Therapy appears to reduce rate of chemotherapy-induced early menopause for women with breast cancer

July 19, 2011
Temporarily suppressing ovarian function with use of the hormone analogue triptorelin reduced the occurrence of early menopause induced by chemotherapy among women with breast cancer, according to a study in the July 20 issue ...

Recommended for you

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.